国产精品九九久久一区hh_无码三级A在线观看_麻豆影视文化传媒APP_欧美三级网址_日韩永久在线观看免费视频

CN

• About Us

  Company Profile

  Chronicle of Events

  Contact Us

• Our Technology

  New Drug R&D

  Production Quality

  Commercialization

  Global Cooperation

• Our Products

  R&D Pipeline

• Our Responsibilities
• News Center
• Investors
• Career

  Talent Development Concept

  Career Opportunities

CN

• Home
• About Us

  Company Profile

  Chronicle of Events

  Contact Us

• Our Technology

  New Drug R&D

  Production Quality

  Commercialization

  Global Cooperation

• Our Products

  R&D Pipeline

• Our Responsibilities
• News Center
• Investors
• Career Development

  Talent Development Concept

  Career Opportunities

News Center

Latest news and media data.

News Center

Latest news and media data.

2019-12-13

「Created in China」 Efforts Take Effect
Sunshine Guojian Finds New Ground in the Field of Immunosuppression

Sunshine Guojian announced recently that Xenopax, the only humanized anti-CD25 monoclonal antibody injection approved for marketing in China, has been officially launched. The monoclonal antibody drug is independently developed by Sunshine Guojian and used for prevention of acute rejection after renal transplantation. It can be combined with the routine immunosuppression regime to significantly improve the survival rate of transplanted organs and the quality of life of patients.

Learn More

2019-12-13

Sunshine Guojian and Numab Collaborate to Develop a Portfolio of Novel Multi-specific Antibodies

SHENYANG, China, SHANGHAI, China, and WAEDENSWIL, Switzerland — December [12], 2019 — 3SBio Inc. (「3SBio」, HKEX:1530) and Numab Therapeutics (「Numab」) announced today on a collaboration agreement, pursuant to which Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Learn More

2019-10-17

First Prescription of Humanized Anti-CD25 Monoclonal Antibody Drug Developed Independently in China
Find New Ground in the Field of Immunosuppress

(October 17, 2019, Shanghai) The first prescription of the humanized anti-CD25 monoclonal antibody drug developed independently in China was issued in Zhongshan Hospital Affiliated to Fudan University today. The monoclonal antibody drug is independently developed by Sunshine Guojian, and is used for prevention of acute rejection after renal transplantation. Professor Zhu Tongyu, Vice President of Zhongshan Hospital Affiliated to Fudan University, said: 「The first prescription of Xenopax means that Chinese transplant recipients can have access to more treatment options, and it also marks that the pharmaceutical capability in the field of immunotherapy in China has reached the international first-class level. Sunshine Guojian is expected to develop more and better biological preparations and make contribution to the improvement of China’s medical capability.」

Learn More

2019-07-29

Great news! China's First Independent R&D Pre-filled Fusion Protein for Injection - YISAIPU Solution Submitted to New Drug Production

(Shanghai, China, 29 July 2019) Today, China’s leading biopharmaceutical company Sunshine Pharmaceuticals Co., Ltd. (01530.HK) announced, the application for new drug production of the antibody fusion protein medicine YISAIPU pre-filled solution (common name: Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ: IgG Fc Fusion Protein for Injection) independently developed by its Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd has been submitted to the National Medical Products Administration and accepted.

Learn More

2019-05-18

YISAIPU Granted GMP Certificate of Indonesia (a PIC/S Member Country)

On May 17, 2019, Sunshine Guojian’s antibody drug YISAIPU was officially granted the GMP certificate in Indonesia.

Learn More

2018-12-24

Shanghai Base Football Club Friendly Match

On December 16, 2018, the friendly match between Sunshine Guojian football team and Quintiles football team went on smoothly under the warm invitation of two teams. After 90 minutes of fierce competition, Sunshine Guojian football team defeated their opponents 4-2.

Learn More

Home pagePrevious1234NextLast page